IGF2R and neoplasm: Notably, authors proposed that in those HCAs associated with an increase in insulin-like growth factor 2 (IGF2) by inactivation of the insulin-like growth factor 2 receptor (IGF2R) gene, a therapy targeting IGF2 could effectively prevent tumor malignancy.